Related Experiment Video
Updated: Jan 25, 2026

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
Published on: March 11, 2021
The cardiac diagnostic work-up in stroke patients-A subanalysis of the Find-AFRANDOMISED trial
Katrin Wasser1, Mark Weber-Krüger2, Falko Jürries2
1Clinic for Neurology, University of Göttingen, Göttingen, Germany.
Insights
Enhanced Holter-ECG monitoring significantly impacts therapeutic decisions in stroke patients by detecting atrial fibrillation. Echocardiography identifies high-risk patients but rarely changes therapy, suggesting a need for further investigation.
Area of Science:
- Cardiology
- Neurology
- Medical Diagnostics
Background:
- The optimal cardiac diagnostic workup for stroke patients remains debated, particularly the roles of echocardiography and prolonged Holter-ECG monitoring.
- Evaluating the impact of detected pathologies on treatment and prognosis is crucial for acute ischemic stroke management.
Purpose of the Study:
- To analyze the impact of echocardiography and Holter-ECG monitoring findings on therapeutic decisions and patient prognosis in acute ischemic stroke.
- To compare the effectiveness of enhanced, prolonged Holter-ECG monitoring versus routine care in guiding treatment.
Main Methods:
- A prospective, multicenter study (Find-AFRANDOMISED) randomized 398 ischemic stroke patients (≥60 years) to enhanced Holter-ECG or usual care.
- Substudy compared therapeutic changes from echocardiography (TTE, TEE) and Holter-ECG (routine vs. enhanced/prolonged) and assessed patient prognosis.
Main Results:
- Enhanced Holter-ECG monitoring detected atrial fibrillation (AF) in 27/200 patients, leading to therapy changes (NNCD 8). Routine ECG found AF in 12/198 (NNCD 17).
- Transesophageal echocardiography (TEE) pathologies changed therapy in 14/89 cases (NNCD 12), while transthoracic echocardiography (TTE) changed therapy in 1/90 cases (NNCD 330).
- Therapeutic decisions were most frequently altered by enhanced and prolonged Holter-ECG monitoring.
Conclusions:
- Enhanced and prolonged Holter-ECG monitoring should be prioritized in future stroke guidelines due to its significant impact on therapeutic decisions.
- Echocardiography identifies high-risk cardiovascular patients but infrequently leads to treatment changes, warranting further investigation by neurocardiologic teams.
Background:
The cardiac diagnostic workup of stroke patients, especially the value of echocardiography and enhanced and prolonged Holter-ECG monitoring, is still a matter of debate. We aimed to analyse the impact of pathologies detected by echocardiography and ECG monitoring on therapeutic decisions and prognosis.
Methods:
Find-AFRANDOMISED was a prospective multicenter study which randomised 398 acute ischemic stroke patients ≥ 60 years to enhanced and prolonged Holter-ECG monitoring or usual stroke unit care. This substudy compared therapeutic consequences of echocardiography and routine Holter-ECG or enhanced and prolonged Holter-ECG monitoring, respectively, and prognosis of patients with or without pathologic findings in echocardiography or Holter-ECG monitoring.
Results:
50.3% received enhanced and prolonged Holter-ECG monitoring and 49.7% routine ECG monitoring. 82.9% underwent transthoracic echocardiography (TTE), 38.9% transesophageal echocardiography (TEE) and 25.6% both procedures. 14/89 TEE pathologies and 1/90 TTE pathology led to a change in therapy, resulting in a number needed to change decision (NNCD) of 12 and 330 (p < 0.001), respectively. In comparison, enhanced and prolonged Holter-ECG monitoring found atrial fibrillation (AF) in 27 of 200 patients, and routine ECG monitoring in twelve of 198 patients, leading to therapeutic changes in all patients (NNCD 8 and 17, respectively, p < 0.001).
Conclusions:
Most changes in therapeutic decisions were triggered by enhanced and prolonged Holter-ECG monitoring, which should therefore play a more prominent role in future guidelines. Echocardiography identifies a patient group at high cardiovascular risk, but rarely result in therapeutic changes. Whether this patient group requires further cardiovascular workup remains unknown. This should be further investigated by interdisciplinary neurocardiologic teams and in appropriate future trials.
Trial Registration:
ClinicalTrials.gov NCT01855035.
More Related Videos
Related Concept Videos
Cardiac Output II: Effect of Stroke Volume on Cardiac Output
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
Cardiac Output and Stroke Volume
In an average resting adult male, the typical cardiac...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...

